A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.
- If tests show that the patient is eligible and they choose to participate in the study,
they will receive a bottle of Gleevec pills. Each pill will be 100mg and the
participant will take 4 pills once daily (400mg). The dose may increase to 400mg twice
a day if the participant's cancer worsens.
- The following study procedures will also be performed at routine intervals throughout
the course of treatment: blood tests, medical history updates; physical exams, Positron
Emission tomography (PET) scan, and Chest/Abdomen/Pelvic CT.
- Participants will be on this study for approximately one year.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the response rate of patients with metastatic mucosal or acral/lentiginous melanoma and chronically sundamaged melanomas to treatment with Gleevec and also to determine the time to progression.
F. Stephen Hodi, MD
Dana-Farber Cancer Institute
United States: Food and Drug Administration
|MD Anderson Cancer Center||Houston, Texas 77030-4096|
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|H. Lee Moffitt Cancer Center||Tampa, Florida 33612|
|University of Chicago||Chicago, Illinois 60637|
|University of Colorado at Denver Health Sciences Center||Denver, Colorado 80045|